Meeting
2023 ASCO Annual Meeting
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies.
Authors
Caixia Li
The First Affiliated Hospital of Soochow University, Suzhou, China
Caixia Li , Jia Wei , Keshu Zhou , Peng Liu , He Huang , Fei Li , Qingqing Cai , Yujun Dong , Shenmiao Yang , Hui Zhou , Xinyou Zhang , Lu Zhang , Zaixing Shi , Zhiyu Liang , Binghao Wu , Depei Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04883957
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7558)
DOI
10.1200/JCO.2023.41.16_suppl.7558
Abstract #
7558
Poster Bd #
109
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.
First Author: Gary Edward Richardson
Poster
2024 ASCO Annual Meeting
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.
First Author: Andrae L. Vandross
Poster
2024 ASCO Genitourinary Cancers Symposium
Preliminary data from a dose-escalation phase 1 study with HP518, an AR PROTAC degrader: Safety, tolerability, pharmacokinetics (PK), and first assessment of anti-tumor activity in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arun Azad
Poster
2023 ASCO Annual Meeting
A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.
First Author: Fei Ma